LYEL Projected Dividend Yield

Lyell Immunopharma Inc ( NASDAQ : LYEL )

Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Co. is building a multi-modality product pipeline. Co.'s primary activities include developing T cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license arrangements, enabling manufacturing activities in support of its product candidate development efforts, organizing and staffing Co., establishing its intellectual property portfolio, regulatory submissions and other preparations to initiate clinical trials, raising capital and providing general and administrative support for these activities.

20 YEAR PERFORMANCE RESULTS